Related Experiment Video

Updated: Jun 11, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Emerging Targets in Non-Small Cell Lung Cancer

Louisa Liu1, Joshua Soler2, Karen L Reckamp1

  • 1Samuel-Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

International Journal of Molecular Sciences
|September 28, 2024
PubMed

Insights

New molecular targets are revolutionizing non-small cell lung cancer (NSCLC) treatment. This review details emerging targets, their mechanisms, and ongoing clinical trials for advanced NSCLC patients.

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Lung cancer presents a significant global health burden.
  • Targetable genomic alterations have transformed non-small cell lung cancer (NSCLC) treatment.
  • Emerging molecular drivers offer new therapeutic avenues.

Purpose of the Study:

  • To review emerging molecular targets in advanced NSCLC.
  • To elaborate on their clinical characteristics and mechanisms.
  • To summarize ongoing clinical trials and preliminary efficacy data.

Main Methods:

  • Literature review of emerging molecular targets in NSCLC.
  • Analysis of clinical characteristics and molecular pathways.
  • Compilation of data from ongoing clinical trials.

Main Results:

  • Identified KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate receptor alpha, ITGB6, and PRMT5 as key emerging targets.
  • Detailed their specific mechanisms and targeted treatment availability.
  • Aggregated data on clinical trial status and preliminary efficacy.

Conclusions:

  • Emerging molecular targets show significant potential for advanced NSCLC.
  • Ongoing clinical trials are crucial for validating these targets.
  • These advancements can guide future NSCLC treatment strategies and improve patient outcomes.
Keywords:
non-small cell lung cancernovel combinatorial approachesoncogene drivertargeted therapies

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K